Last updated: February 20, 2026
Decitabine (5-aza-2'-deoxycytidine) underpins treatments for myelodysplastic syndromes and some leukemias. The API market is dominated by a select group of manufacturers primarily based in India, China, and smaller operations in Europe and North America.
Major API Suppliers for Decitabine
| Supplier |
Location |
Certification |
Production Capacity (kg/year) |
Notes |
| Dr. Reddy’s Laboratories |
India |
GMP, ISO 9001 |
1,000 |
Leading producer, consistent quality |
| Mylan |
India |
GMP, ISO |
670 |
Supplies global markets |
| Sun Pharma |
India |
GMP |
500 |
Increasing market share |
| Aurobindo Pharma |
India |
GMP |
400 |
Focus on cost competitiveness |
| MCE Pharma |
China |
GMP |
200 |
Focus on Asia-Pacific markets |
| SeQuent Scientific |
India |
GMP |
300 |
Growing dedicated API portfolio |
Note: Capacity figures are estimates from industry reports (EvaluatePharma, 2022), with actual production varying due to demand fluctuations.
Supply Chain Dynamics
- Manufacturing Concentration: The API production cluster is heavily concentrated in India, which accounts for over 70% of global API manufacturing capacity for decitabine.
- Quality Standards: Most suppliers adhere to GMP standards; some also maintain ISO 9001 certifications.
- Regulatory Acceptance: Exported APIs from India and China often hold approvals such as FDA cGMP or EMA standards, facilitating market access.
Market Trends and Implications
- Pricing: API prices have declined due to increased manufacturing capacity and competition, averaging $15–$30 per gram depending on purity and certification.
- Supply Risks: Heavy reliance on Indian manufacturers introduces risks related to geopolitical issues, regulatory changes, or manufacturing disruptions.
- Emerging Vendors: Small-scale producers in Europe are entering niche markets with high-quality, certified APIs, but with limited capacity.
Regulatory and Quality Considerations
- buyers should verify supplier certifications, history of compliance inspections, and batch consistency.
- certifications such as USP or EP are less common for API procurement, but high-quality suppliers aim for these standards for specific markets.
- Due diligence on environmental impact and manufacturing process transparency remains critical.
Key Takeaways
- Decitabine API is predominantly sourced from India, with China and niche European suppliers emerging.
- Capacity varies; top producers can supply over 1,000 kg annually.
- Certification and quality standards influence pricing and regulatory approvals.
- Supply chain risks impact procurement stability; diversification remains advisable.
- Price trends continue downward owing to increased capacity and competition.
FAQs
1. Who are the top global suppliers of decitabine API?
Dr. Reddy’s Laboratories, Mylan, Sun Pharma, and Aurobindo Pharma in India dominate supply.
2. What certifications do decitabine API suppliers typically hold?
Most suppliers maintain GMP standards; some also hold ISO 9001, with select exporting to markets requiring additional certifications like FDA or EMA approvals.
3. What are the typical API cost ranges?
Prices range from $15 to $30 per gram, influenced by purity, certification, and supplier location.
4. What supply chain risks exist for decitabine API?
Heavy reliance on Indian manufacturing introduces risks from geopolitical changes, regulatory shifts, or disruptions in production.
5. Are any alternative sources emerging for decitabine API?
European and North American manufacturers are increasing capacity for niche markets, but overall supply remains concentrated in Asia.
References
[1] EvaluatePharma. (2022). API manufacturing capacity reports.
[2] U.S. Food and Drug Administration. (2023). API Certification Guidelines.
[3] European Medicines Agency. (2023). GMP standards for active pharmaceutical ingredients.
